Investor FAQs
 Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell's most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of RDEB. Fibrocell is also developing FCX-013 for the treatment of moderate to severe localized scleroderma, and is currently enrolling the Phase 1 portion of a Phase 1/2 clinical trial. Fibrocell's gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NASDAQ: XON), a leader in synthetic biology.

 Fibrocell is located at 405 Eagleview Boulevard, Exton, PA 19341, USA. The main office telephone number is (484) 713-6000 and fax number is (484) 713-6001.

 Fibrocell is incorporated in the state of Delaware.

 December 31

 The company’s stock is traded on the NASDAQ Global Market. The ticker symbol is FCSC.

 Send communications about transfer requirements, lost certificates and changes of address to:
Broadridge Corporate Issuer Solutions
P.O. Box 1342
Brentwood, NY 11717

Overnight Mail Address:
Broadridge Corporate Issuer Solutions
1155 Long Island Avenue
Edgewood, NY 11717
Phone #: 1-877-830-4936
Website: https://investor.broadridge.com/

 Shares cannot be purchased directly through the company.

 This information appears in the annual proxy statement posted on our SEC Filings page and may also be found with prior proxy filings at www.sec.gov.

  PricewaterhouseCoopers LLP
Two Commerce Square
Suite 1700
2001 Market Street
Philadelphia, PA 19103


The company’s news releases are archived on our Press Releases pages.

 You can view the SEC filings for Fibrocell on our SEC Filings page or at www.sec.gov.

 Visit our Careers page to learn more about career opportunities

 Click here to submit your inquiries.

Printer Friendly Version E-mail this page RSS E-mail Alerts Download Financial Tear Sheet